Cato BioVentures’ Advanced Pain Remedies Gets $3M Grant From National Cancer Institute
Cato BioVentures’ Advanced Pain Remedies of North Carolina received a $3 million from the National Cancer Institute to develop its SP-SAP in end-stage cancer patients with intractable pain. Advance Pain plans to use the financing over the next three years to start a clinical program for SP-SAP. Cato BioVentures is the venture capital affiliate of Cato Research Ltd.
10 January 2011•4 mins read
